Antipsychotic Drugs Market size was valued at USD 13.8 Billion in 2022 and is expected to reach USD 25.92 Billion By 2030 and grow at a CAGR of 8.2% over the forecast period of 2023-2030.

The Antipsychotic Drugs Market Share Report provides a comprehensive analysis of the global antipsychotic drugs market, highlighting key trends, growth drivers, challenges, and opportunities. The report aims to assist industry stakeholders in making informed decisions and formulating effective strategies.

The antipsychotic drugs market has witnessed significant growth in recent years, driven by the rising prevalence of mental disorders such as schizophrenia, bipolar disorder, and depression. These conditions affect millions of people worldwide, leading to a growing demand for effective treatment options.

Get Free PDF Sample Report: https://www.snsinsider.com/sample-request/2939

Antipsychotic drugs are primarily used to manage symptoms associated with psychosis, including hallucinations, delusions, and disorganized thinking. They work by targeting neurotransmitters in the brain to restore chemical imbalances that contribute to these symptoms. The market offers a wide range of antipsychotic medications, including both first-generation (typical) and second-generation (atypical) drugs.

In recent years, there has been a shift towards atypical antipsychotics due to their improved efficacy and reduced side effects compared to typical antipsychotics. This trend is expected to continue driving market growth as healthcare providers increasingly prescribe atypical medications as a first-line treatment option.

KEY MARKET SEGMENTS

By Therapeutic Class

• First-Generation
• Second-Generation

By Application

• Schizophrenia
• Dementia
• Bipolar Disorder
• Depression
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Major Players Listed in the Report are as Follows:

AstraZeneca Plc., Bristol-Myers Squibb, Pfizer Inc., Johnson & Johnson (Janssen Pharmaceuticals), dr. Reddy Laboratories Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Alkermes Plc., Otsuka Holdings Co. Ltd., Abbvie lnc. and the final reports list additional participants.

About US:

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

Contact Us:

Akash Anand – Head of Business Development & Strategy,

info@snsinsider.com,

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)